To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 × 10 −29 and rs7755224, combined P = 2.00 × 10 −19 ; r 2 = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 × 10 −9 ).
Non-Hodgkin lymphoma (NHL) is a complex group of B-and T-cell neoplasms with >300,000 new cases diagnosed worldwide each year (see URLs). Family and epidemiological studies suggest an important genetic role in the etiology of lymphoma 1 , but the inherited genetic basis of the disease is largely unknown. Recently, we conducted a genomewide association study (GWAS) of three common histological subtypes of NHL-follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and diffuse large B-cell lymphoma (DLBCL)-using a pooled DNA genotyping strategy 2 . Due to experimental and technical noise associated with use of pooled DNA, we conducted a new individual genotyping-based study on a larger subset of individuals with NHL (cases) and unaffected controls using a three-stage GWAS design ( Supplementary Table 1 and Supplementary Fig. 1) .
In stage 1, we conducted a GWAS using a subset of samples (SF1 study) chosen from a larger population-based case-control study of NHL based in the San Francisco Bay Area 3 . After applying qualitycontrol metrics (Supplementary Methods), we included 213 follicular lymphoma, 211 CLL/SLL and 257 DLBCL cases and 750 controls in the final statistical analysis of stage 1. The genome-wide results for follicular lymphoma, CLL/SLL and DLBCL are represented in Supplementary Figure 2 , where overall, 18 SNPs showed unadjusted trend P values below a 10 −5 threshold (Supplementary Table 2 ). The most notable findings were for SNPs associated with follicular lymphoma in the major histocompatibility complex (MHC) region on chromosome 6, concentrated around two independent peaks at 6p21.33 and 6p21.32 (r 2 < 0.01; Fig. 1a ). The strongest signal in 6p21.33 was located at PSORS1 (encoding the psoriasis susceptibility region 1) (rs1265086, trend P = 3.34 × 10 −6 ; Supplementary Table 3) , where we previously detected a follicular lymphoma susceptibility locus 2 . The 6p21.32 association peak is located in a region encompassing the HLA-DR and HLA-DQ genes. Here, eight SNPs exhibited trend P ≤ 10 −4 ( Supplementary Table 3 ).
In stage 2, we genotyped 40 SNPs with the lowest trend P values for each NHL subtype (Supplementary Tables 4-6) in two independent population-based case-control studies (Scandinavian Lymphoma Etiology follicular lymphoma case-control study (SCALE) 4 for follicular lymphoma and Mayo Clinic NHL/CLL GWAS and Genetic Epidemiology of CLL consortium (Mayo-GEC) 5 for CLL/SLL and in a separate sample of 118 DLBCL population-based cases and 651 controls (SF1B study) drawn from the same population as that used in SF1 ( Supplementary Table 1 and Supplementary Fig. 1 ). Seven SNPs were associated with follicular lymphoma risk (using a significance threshold of P < 0.05) in the SCALE study (Supplementary Table 7 ). The two SNPs with the lowest P values (rs7755224, allelic P = 6.30 × 10 −5 , and rs10484561, allelic P = 1.20 × 10 −5 ) are located in the MHC class II region at 6p21.32. They are in complete linkage disequilibrium (LD) (r 2 = 1.0) and lie, respectively, 16 kb and 29 kb upstream of HLA-DQB1. Four additional SNPs were associated with follicular lymphoma in the MHC region at 6p21.33, including the two SNPs (rs6457327, allelic P = 2.90 × 10 −2 , and rs2517448, allelic P = 3.45 × 10 −2 ) previously reported in our pooled-DNA GWAS 2 .
Two SNPs with trend P < 0.05 were positively associated with CLL/ SLL risk in the Mayo-GEC study (rs735665, trend P = 2.64 × 10 −3 , and rs484458, trend P = 6.43 × 10 −3 ; Supplementary Table 7 ). Located in an intergenic region on 11q24.1, rs735665 was reported as a risk allele for CLL in a previous genome scan 6 . Notably, two other SNPs (rs872071 and rs9378805) reported to be associated with CLL in that study were ranked among the top 100 CLL/SLL SNPs in our stage 1 GWAS (trend P = 7.17 × 10 −4 and trend P = 1.75 × 10 −4 , respectively). None of the SNPs genotyped in stage 2 for DLBCL showed evidence of association with disease risk (using a significance threshold of P < 0.05). Failure to identify associated alleles may have been due to the heterogeneity of DLBCL as evidenced by gene expression and immunophenotyping studies.
In stage 3, we genotyped the nine SNPs associated with follicular lymphoma and CLL/SLL risk in 873 follicular lymphoma, 471 CLL/SLL and 916 DLBCL cases and 4,470 controls recruited from six casecontrol studies of European descent participating in the InterLymph Consortium ( Supplementary Table 1 and Supplementary Fig. 1 ). Again, rs10484561 was associated with increased follicular lymphoma risk across all studies, with trend P values ranging from 2.21 × 10 −2 to 1.40 × 10 −10 ( Table 1 ). The combined P value reached 1.12 × 10 −29 in the meta-analysis of samples from all three stages (combined odds ratio (OR) = 1.95, 95% CI 1.72-2.22; Supplementary Table 8 and Supplementary Fig. 3 ). No evidence was found of heterogeneity across studies (Cochran's Q statistic = 5.61, degrees of freedom (d.f.) = 7, P = 0.5857, I 2 heterogeneity index = 0%). Likewise, rs7755224 was associated with follicular lymphoma in the meta-analysis from all stages (combined P = 2.00 × 10 −19 , OR = 2.07, 95% CI 1.76-2.42; Supplementary Table 8 and Supplementary Fig. 4) , and no evidence was found of significant heterogeneity (Q = 5.42, d.f. = 3, P = 0.1438, I 2 = 44.6%). Although the association between rs6457327 and follicular lymphoma was replicated in stage 2 and in three other independent sample sets 2 , this association was poorly replicated in the smaller studies from stage 3, resulting in a weaker combined P value (P = 6.64 × 10 −6 , OR = 0.68, 95% CI 0.58-0.79; Supplementary  Table 8 ) than previously reported 2 ( Supplementary Table 9 ).
For CLL/SLL, rs735665 had a trend P = 3.58 × 10 −4 in stage 3 and a combined P = 4.24 × 10 −9 in the meta-analysis of all samples (OR = 1.81, 95% CI 1.50-2.20; Supplementary Table 8 ). This finding confirms the previously reported association of rs735665 with CLL risk 6 .
To search for additional follicular lymphoma-associated variants that were not genotyped in the HLA-DQB1 region in stage 1, we imputed SNP genotypes in a 500-kb region centered on rs10484561 ( Fig. 1b) . We identified four SNPs with imputed P < 10 −3 that were in complete LD with rs10484561 (D′ = 1, r 2 = 1 in the HapMap European CEU population) but none showed stronger signals than rs10484561 or rs7755224 ( Supplementary Table 10 ). These SNPs are located in a 100-kb region of relatively high LD on chromosome 6p21.32 that covers HLA-DQB1 and HLA-DQA1 and is in close proximity to HLA-DRB1. Logistic regression analysis conditional on the associated SNPs in the region suggested that none of these SNPs represented independent signals ( Supplementary Table 11 ) and that a single locus or haplotype in LD with rs10484561 and/or rs7755224 may harbor the causal variant(s). Analysis of SNP interactions and preliminary functional analyses did not provide further refinement of the signal (Supplementary Methods) . However, one of the imputed SNPs, rs6457614, reported as a tag SNP for the HLA-DQB1*0501 allele in European, African and Japanese populations 7 suggested that the association signal may be driven by this protein variant. To verify our imputation, we genotyped rs6457614 in the SF1 study. We found 99% concordance between imputed and observed genotypes for rs6457614, which was in strong LD with rs10484561 (D′ = 0.99, r 2 = 0.95 in controls). Because HLA-DRB1*0101 and HLA-DQA1*0101 form the most frequent haplotype containing HLA-DQB1*0501 in European-American populations 8 , we also genotyped tag SNPs for these two MHC class II alleles (rs4947332 in HLA-DRB1*0101 and rs1794265 in HLA-DQA1*0101) 7 in SF1. We found that markers for an extended haplotype that includes HLA-DRB1*0101-HLA-DQA1*0101-HLA-DQB1*0501-rs104845561 were associated with follicular lymphoma risk (OR = 2.07, 95% CI = 1.40-3.06, P = 2.32 × 10 −4 ).
Several small studies have reported links between MHC class II alleles and NHL [9] [10] [11] , with somewhat conflicting results that may be attributable to small sample size, the combined analysis of mixed NHL subtypes figure 1 Linkage disequilibrium and association results for the follicular lymphoma-associated regions in the MHC. (a) Trend P values (as −log 10 ) are shown for SNPs genotyped in the MHC region between positions 30,000 Mb and 35,000 Mb, where two independent follicular lymphoma-associated peaks were found. The first peak, represented by rs6457327 (in yellow), is located at 6p21.33 in the MHC class I region. The second independent peak, represented by rs10484561 (in green), is located at 6p21.32 in the MHC class II region. A 500-kb region centered on rs10484561 is demarcated in red and shown separately in panel b. (b) SNPs genotyped (in black) and imputed (in red) in stage 1 in the 500-kb region centered on rs10484561 at 6p21.32. Imputations were based on data from HapMap Phase II release no. 22 in the CEU population. The figure was constructed using the snp.plotter R package (see URLs). and/or differences in the ethnic groups being analyzed 11 . In a large pooled study within the InterLymph Consortium, the variant allele for TNF −308A (rs1800629) and a TNF-LTA haplotype located in the MHC class III region were positively associated with DLBCL risk, but no association was found for follicular lymphoma 12 . Further, MHC class I and class II alleles have been evaluated in the context of TNF extended haplotypes, which revealed independent positive associations for TNF −308A and HLA-B*0801 alleles in risk of DLBCL 13 . These loci were not in LD with rs10484561 in our controls (r 2 = 0.014 for rs10484561 and TNF −308A; r 2 = 0.007-0.001 for rs10484561 and HLA-B*0801 tag SNPS 7 ), suggesting that our signal is not driven by these MHC class III and class I loci. Notably, the association found here in the MHC class II region also appears to be independent of the follicular lymphoma susceptibility locus at PSORS1, as the LD block at HLA-DRB1-HLA-DQA1-HLA-DQB1 is located 1.43 Mb downstream of the PSORS1 locus (Fig. 1a) , and the LD measurement between rs6457327 and rs10484561 (r 2 < 0.01) in our controls and in the HapMap CEU population indicates no correlation between these loci. Results from conditional logistic regression analysis adjusted for the additive effects of rs6457327 in the SF1 study provided additional evidence for an independent role of rs10484561 (P = 3.46 × 10 −5 ) in follicular lymphoma risk.
In conclusion, we have identified a new follicular lymphoma susceptibility locus at chromosome 6p21.32, providing evidence that genetic variation in the MHC class II region is strongly associated with follicular lymphoma susceptibility. These loci appear to be part of an extended haplotype that includes HLA-DRB1*0101-HLA-DQA1*0101-HLA-DQB1*0501. Of note, although rs10484561 showed a trend toward association in DLBCL in the SF1 population (trend P = 0.0358), we did not observe markedly significant associations between the MHC region and risk of CLL/SLL or DLBCL (Supplementary Fig. 5 ), which suggests that the influence of MHC genetic variation differs by NHL subtype.
URLs. Globocan database, http://globocan.iarc.fr; snp.plotter R package, http://cbdb.nimh.nih.gov/~kristin/snp.plotter.html. 
